Publication | Closed Access

Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia

Metabolic SyndromeCardiovascular DiseaseMedicineDiabetesPhysiologyHyperlipidemiaLipoprotein MetabolismBaseline Triglyceride LevelsRosuvastatin TreatmentPharmacologyAtherosclerosisDyslipidemiaPrimary HyperlipidemiaHealth Sciences